Artiva Biotherapeutics awarded COO, CLO and Compliance Officer Bush Jennifer 45,000 shares at $0 per share and 135,000 derivative securities on September 9, 2026. The transactions left her with 374,529 shares and 135,000 derivative securities, equal to about 12.0% and 100.0% of the respective resulting holdings.
Key Highlights
- Bush Jennifer’s post-transaction holding reached 374,529 Artiva Biotherapeutics shares.
- The share award represented about 12.0% of her resulting share holding.
- Her 135,000 derivative securities represented about 100.0% of her resulting derivative securities holding.
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) awarded Bush Jennifer, its COO, CLO and Compliance Officer, 45,000 shares at $0 per share. The transaction also covered 135,000 derivative securities on September 9, 2026.
Award Covers Shares and Derivative Securities
Bush Jennifer’s resulting share holding was 374,529 shares. Her resulting derivative securities holding was 135,000 securities. The award was recorded on September 9, 2026, and the share consideration was $0 per share.
Holdings Show Separate Share and Derivative Stakes
The 45,000-share transaction represented about 12.0% of Bush Jennifer’s resulting share holding. The 135,000 derivative securities represented about 100.0% of her resulting derivative securities holding. The two percentages apply to the respective holdings disclosed after the transactions.
FAQs
Q: How many shares did Artiva Biotherapeutics award Bush Jennifer?
A: Artiva Biotherapeutics awarded Bush Jennifer 45,000 shares at $0 per share. The transaction was recorded on September 9, 2026, under transaction code A.
Q: What was the impact on Bush Jennifer’s ARTV holdings?
A: Bush Jennifer’s resulting Artiva Biotherapeutics share holding was 374,529 shares. The transaction represented about 12.0% of that resulting share holding.
Q: How many derivative securities did Bush Jennifer receive?
A: Bush Jennifer received 135,000 derivative securities from Artiva Biotherapeutics. That amount represented about 100.0% of her resulting derivative securities holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.